Cooperative Agreement U01CA294536
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.353
Assistance Type
Cooperative Agreement
Place of Performance
San Francisco, CA 94115, USA
Similar Awards
This $1,128,990 Cooperative Agreement award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) will fund the Myeloma Multidimensional Precancer Atlas (MMPCA) project at the Dana-Farber Cancer Institute. The project aims to construct a comprehensive spatial and temporal atlas of precursor stages of multiple myeloma (MM) to understand genomic and microenvironmental alterations across the disease spectrum. Key objectives include: Mapping spatial...
This Project Grant award from the National Cancer Institute (NCI), under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), provides $369,354.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the tumor immune microenvironment and response to immunotherapy among different racial and ethnic populations with breast cancer. The key objectives of this research project are: 1) to determine how frequently women of different...
The National Cancer Institute (NCI) awarded a $2,520,895 Cooperative Agreement grant under the Cancer Centers Support Grants (CFDA 93.397) program to The Regents of the University of California, San Francisco (UCSF). The 5-year award, effective August 1, 2025, supports research projects aimed at improving cancer health disparities by investigating the interplay of tumor genomic and immune characteristics with social and structural drivers of health. The funded projects focus on three diverse...
This $1,018,682 Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) aims to construct a spatiotemporal atlas of human follicular lymphoma (FL) transformation to diffuse large B-cell lymphoma (DLBCL) and angioimmunoblastic T-cell lymphoma (AITL) evolution. The award to Yale University will leverage single-cell and spatial omics technologies to map the major cell types, mutational landscapes,...
The National Cancer Institute (NCI) awarded a $1,032,520 Cooperative Agreement under the 21st Century Cures Act - Beau Biden Cancer Moonshot (CFDA 93.353) program to the Washington University to establish the Human Prostate Tumor Atlas Center (HPTAC). Over the 5-year project period from Sep 1, 2024 to Aug 31, 2029, the HPTAC will develop a molecularly resolved spatial atlas of prostate cancer (PCA) that integrates multi-omics, imaging, and clinical data. The atlas will elucidate PCA...
This $1,069,188 Cooperative Agreement award, provided by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), supports a collaborative research project to construct a comparative spatial atlas of low-grade gliomas. The research team from the University of California, Los Angeles (UCLA) Neurosurgery and the California Institute of Technology (Caltech) Spatial Single Cell team will expand on their preliminary data to generate an...
This federal Cooperative Agreement award, funded by the National Cancer Institute under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353), aims to create a comprehensive 3D atlas depicting the progression of pancreatic cancer precursor lesions to invasive pancreatic ductal adenocarcinoma (PDAC) in individuals with genetic defects in DNA repair genes (BRCA1, BRCA2, PALB2). The $1,035,138 award, with a period of performance from Sep 1, 2024 to Aug 31, 2029, will support...
This Cooperative Agreement award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) provides $1,979,214 to the University of Texas MD Anderson Cancer Center to construct a three-dimensional (3D) ovarian cancer atlas. The atlas will characterize high-grade serous ovarian cancer (HGSOC) metastasis and the development of intrinsic therapeutic resistance using advanced molecular and cellular profiling platforms. The project...
This $958,434 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The Leland Stanford Junior University to elucidate the molecular mechanisms of RET kinase regulation in human epidermis and define RET-regulated impacts on the tumor immune microenvironment. The long-term goal is to develop topical selective RET inhibitors for effective therapeutic prevention of cutaneous squamous cell carcinoma (CSCC). The proposed research...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot federal grant program (CFDA 93.353), will fund the construction of a three-dimensional (3D) multimodal molecular atlas of colorectal cancer (CRC) across different ages of onset. The $1,063,411 award to Vanderbilt University will support spatial mapping of tumor progression from precancerous to cancerous states, utilizing cutting-edge technologies such as...